89bio, Inc. (ETNB)

8.58 -0.34 (-3.81%) At close: 04:00PM EDT

89bio, Inc.

142 Sansome Street
Second Floor
San Francisco, CA 94104
United States
415 432 9270
https://www.89bio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 70

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Rohan Palekar	CEO & Director	1.06M	N/A	1966
Mr. Quoc Le-Nguyen	Chief Technical Operations Officer & Head of Quality	702.87k	N/A	1968
Dr. Harry Mansbach M.D.	Chief Medical Officer	732.87k	N/A	1965
Mr. Ryan Stephen Martins	Chief Financial Officer	N/A	N/A	1979
Mr. Shiva K. Natarajan CPA	Senior Vice President of Finance & Principal Accounting Officer	N/A	N/A	1966
Ms. Annie J. Chang M.B.A.	VP of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Amanda Kurihara	Vice President of People & Culture	N/A	N/A	N/A
Ms. Yun Bai Ph.D.	VP and Head of Chemistry, Manufacturing & Controls ( CMC )	N/A	N/A	N/A
Ms. Melissa Abel	Senior Vice President of Commercial Strategy	N/A	N/A	N/A
Mr. Paul Shin	Senior Vice President of R&D Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Corporate governance

89bio, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.